Envista (NYSE:NVST) Raised to “Outperform” at Robert W. Baird

Robert W. Baird upgraded shares of Envista (NYSE:NVST) from a neutral rating to an outperform rating in a research note issued to investors on Tuesday, Marketbeat Ratings reports. Robert W. Baird currently has $23.00 price objective on the stock, up from their previous price objective of $21.00.

Other equities analysts also recently issued research reports about the company. Piper Sandler cut their target price on Envista from $18.00 to $17.00 and set a “neutral” rating for the company in a research report on Wednesday, April 30th. Morgan Stanley set a $16.00 target price on Envista in a research report on Tuesday, April 15th. Bank of America dropped their price target on Envista from $26.00 to $23.00 and set a “buy” rating for the company in a report on Tuesday, April 29th. Wells Fargo & Company set a $19.00 price target on Envista in a report on Saturday, March 8th. Finally, UBS Group dropped their price target on Envista from $21.00 to $18.00 and set a “neutral” rating for the company in a report on Monday, May 5th. One analyst has rated the stock with a sell rating, nine have given a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $20.23.

Envista Price Performance

Envista stock opened at $18.00 on Tuesday. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.04 and a quick ratio of 1.76. The company has a market capitalization of $3.05 billion, a PE ratio of -2.77, a price-to-earnings-growth ratio of 1.27 and a beta of 0.97. Envista has a one year low of $14.22 and a one year high of $23.00. The business has a 50 day simple moving average of $16.58 and a 200 day simple moving average of $18.78.

Envista (NYSE:NVST) last posted its earnings results on Thursday, May 1st. The company reported $0.24 EPS for the quarter, topping the consensus estimate of $0.20 by $0.04. The business had revenue of $616.90 million during the quarter, compared to the consensus estimate of $608.17 million. Envista had a positive return on equity of 3.86% and a negative net margin of 44.56%. Envista’s revenue was down 1.1% on a year-over-year basis. During the same quarter last year, the company earned $0.26 EPS. On average, sell-side analysts forecast that Envista will post 1 EPS for the current fiscal year.

Institutional Investors Weigh In On Envista

Institutional investors have recently made changes to their positions in the stock. Venturi Wealth Management LLC grew its stake in shares of Envista by 528.4% during the fourth quarter. Venturi Wealth Management LLC now owns 1,948 shares of the company’s stock worth $38,000 after purchasing an additional 1,638 shares during the period. UMB Bank n.a. grew its stake in shares of Envista by 214.4% during the first quarter. UMB Bank n.a. now owns 2,094 shares of the company’s stock worth $36,000 after purchasing an additional 1,428 shares during the period. Mitsubishi UFJ Trust & Banking Corp bought a new position in Envista during the fourth quarter worth about $86,000. KBC Group NV grew its stake in Envista by 63.9% in the fourth quarter. KBC Group NV now owns 7,903 shares of the company’s stock valued at $152,000 after acquiring an additional 3,082 shares during the period. Finally, Palouse Capital Management Inc. grew its stake in Envista by 14.4% in the first quarter. Palouse Capital Management Inc. now owns 9,444 shares of the company’s stock valued at $163,000 after acquiring an additional 1,186 shares during the period.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.